Evidence of β-cell dedifferentiation in human type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 3, 2016, Pages 1044-1054

  Cinti, Francesca ^a,c   Bouchi, Ryotaro ^a   Kim Muller, Ja Young ^a   Ohmura, Yoshiaki ^b   Sandoval, P R ^b   Masini, Matilde ^d   Marselli, Lorella ^d   Suleiman, Mara ^d   Ratner, Lloyd E ^b   Marchetti, Piero ^d   Accili, Domenico ^a  

^a Department of Medicine ^*  (United States)

^b Columbia University College of Physic and Surg ^*  (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ALDEHYDE DEHYDROGENASE ISOENZYME 1A3; CELL MARKER; GLUCAGON; SOMATOSTATIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; INSULIN; NKX6-1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR FKHR;

ARTICLE; CELL COUNT; CELL DEDIFFERENTIATION; CELL LINEAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOCRINE CELL; GLUCAGON RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGAN DONOR; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SOMATOSTATIN RELEASE; CHEMISTRY; ELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; METABOLISM; PANCREAS ISLET ALPHA CELL; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); SOMATOSTATIN CELL;

CELL DEDIFFERENTIATION; DIABETES MELLITUS, TYPE 2; FORKHEAD BOX PROTEIN O1; FORKHEAD TRANSCRIPTION FACTORS; GLUCAGON; GLUCAGON-SECRETING CELLS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN-SECRETING CELLS; MICROSCOPY, ELECTRON; SOMATOSTATIN; SOMATOSTATIN-SECRETING CELLS;

EID: 84960841640     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2860     Document Type: Article

References (47)

1. Ferrannini E. The stunnedβ cell: a brief history. Cell Metab. 2010; 11:349-352.
2. Defronzo RA, Tripathy D, Schwenke DC, et al. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes. 2013;62:3920-3926.
3. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787-794.
4. Levy J, Atkinson AB, Bell PM, Mc Cance DR, Hadden DR. β-Cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med. 1998;15:290-296.
5. Savage PJ, Bennion LJ, Flock EV, et al. Diet-induced improvement of abnormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus. J Clin Endocrinol Metab. 1979;48:999-1007.
6. Marselli L, Suleiman M, Masini M, et al. Are we overestimating the loss of β cells in type 2 diabetes? Diabetologia. 2014;57:362-365.
7. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl JMed. 2006;355:2427-2443.
8. U.K. Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-865.
9. Butler PC, Meier JJ, Butler AE, Bhushan A. The replication of β cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab. 2007;3:758-768.
10. Talchai C, Lin HV, Kitamura T, Accili D. Genetic and biochemical pathways of β-cell failure in type 2 diabetes. Diabetes Obes Metab. 2009;11(suppl 4):38-45.
11. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell. 2012;150:1223-1234.
12. Taylor BL, Liu FF, Sander M. Nkx6.1is essential for maintaining the functional state of pancreatic β cells. Cell Rep. 2013;4:1262-1275.
13. Puri S, Akiyama H, Hebrok M. VHL-mediated disruption of Sox9 activity compromises β-cell identity and results in diabetes mellitus. Genes Dev. 2013;27:2563-2575.
14. Guo S, Dai C, Guo M, et al. Inactivation of specific β cell transcription factors in type 2 diabetes. J Clin Invest. 2013;123:3305-3316.
15. Wang Z, York NW, Nichols CG, Remedi MS. Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab. 2014;19:872-882.
16. Brereton MF, Iberl M, Shimomura K, et al. Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. Nat Commun. 2014;5:4639.
17. Dunning BE, Gerich JE. The role of a-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev. 2007;28:253-283.
18. Yoon KH, Ko SH, Cho JH, et al. Selective β-cell loss and a-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab. 2003;88:2300-2308.
19. Dor Y, Glaser B. β-Cell dedifferentiation and type 2 diabetes. NEngl J Med. 2013;368:572-573.
20. White MG, Marshall HL, Rigby R, et al. Expression of mesenchymal and a-cell phenotypic markers in islet β-cells in recently diagnosed diabetes. Diabetes Care. 2013;36:3818-3820.
21. Lukinius A, Stridsberg M, Wilander E. Cellular expression and specific intragranular localization of chromogranin A, chromogranin B, and synaptophysin during ontogeny of pancreatic islet cells: an ul-trastructural study. Pancreas. 2003;27:38-46.
22. Kitamura T, Kitamura YI, Kobayashi M, et al. Regulation of pancreatic juxtaductal endocrine cell formation by Fox O1. Mol Cell Biol. 2009;29:4417-4430.
23. Marchetti P, Bugliani M, Lupi R, et al. The endoplasmic reticulum in pancreatic β cells of type 2 diabetes patients. Diabetologia. 2007; 50:2486-2494.
24. Wang X, Misawa R, Zielinski MC, et al. Regional differences in islet distribution in the human pancreas-preferential β-cell loss in the head region in patients with type 2 diabetes. PLoS One. 2013;8: e67454.
25. Masini M, Bugliani M, Lupi R, et al. Autophagy in human type 2 diabetes pancreatic β cells. Diabetologia. 2009;52:1083-1086.
26. Masini M, Marselli L, Bugliani M, et al. Ultrastructural morpho-metric analysis of insulin secretory granules in human type 2 diabetes. Acta Diabetol. 2012;49(suppl 1):S247-S252.
27. Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes. 2002;51(suppl 1):S134-S137.
28. Del Guerra S, Lupi R, Marselli L, et al. Functional and molecular defects ofpancreatic islets in human type 2 diabetes. Diabetes. 2005; 54:727-735.
29. Bugliani M, Liechti R, Cheon H, et al. Microarray analysis of isolated human islet transcriptome in type 2 diabetes and the role of the ubiquitin-proteasome system in pancreatic β cell dysfunction. Mol Cell Endocrinol. 2013;367:1-10.
30. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic β-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10(suppl 4):32-42.
31. Al-Masri M, Krishnamurthy M, Li J, et al. Effect of forkhead box O1 (FOXO1) on β cell development in the human fetal pancreas. Diabetologia. 2010;53:699-711.
32. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle. 2011;10:1378-1384.
33. Kim-Muller JY, Zhao S, Srivastava S, et al. Metabolic inflexibility impairs insulin secretion and results in MODY-like diabetes in triple Fox O-deficient mice. Cell Metab. 2014;20:593-602.
34. Henquin JC, Accili D, Ahren B, Boitard C, Seino S, Cerasi E. Long in the shade, glucagon re-occupies centre court. Diabetes Obes Metab. 2011;13(suppl 1):v-viii.
35. Spijker HS, Ravelli RB, Mommaas-Kienhuis AM, et al. Conversion of mature human β-cells into glucagon-producing a-cells. Diabetes. 2013;62:2471-2480.
36. Polonsky KS. The past 200 years in diabetes. N Engl J Med. 2012; 367:1332-1340.
37. Mezza T, Muscogiuri G, Sorice GP, et al. Insulin resistance alters islet morphology in nondiabetic humans. Diabetes. 2014;63:994-1007.
38. Wang J, Cortina G, Wu SV, et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N Engl J Med. 2006;355:270-280.
39. Rovira M, Scott SG, Liss AS, Jensen J, Thayer SP, Leach SD. Isolation and characterization of centroacinar/terminal ductal progenitor cells in adult mouse pancreas. Proc Natl Acad Sci USA. 2010; 107:75-80.
40. Suzuki T, Kadoya Y, Sato Y, et al. The expression of pancreatic endocrine markers in centroacinar cells of the normal and regenerating rat pancreas: their possible transformation to endocrine cells. Arch Histol Cytol. 2003;66:347-358.
41. Li J, Feng ZC, Yeung FS, et al. Aldehyde dehydrogenase 1 activity in the developing human pancreas modulates retinoic acid signalling in mediating islet differentiation and survival. Diabetologia. 2014; 57:754-764.
42. Kitamura YI, Kitamura T, Kruse JP, et al. Fox O1 protects against pancreatic β cell failure through Neuro D and Maf A induction. Cell Metab. 2005;2:153-163.
43. Greenwood RH, Mahler RF, Hales CN. Improvement in insulin secretion in diabetes after diazoxide. Lancet. 1976;1:444-447.
44. Wajchenberg BL. β-Cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28:187-218.
45. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741-744.
46. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371:1753-1760.
47. Atkinson MA, Bluestone JA, Eisenbarth GS, et al. How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes. 2011;60:1370-1379.